{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"}],"units":"Participants"}],"description":"An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of retifanlimab and within 90 days of the last administration of retifanlimab.","groups":[{"description":"Participants received retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).","id":"OG000","title":"Retifanlimab 500 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Evaluable Population: all enrolled participants who received at least 1 dose of study drug","reportingStatus":"POSTED","timeFrame":"up to 913 days","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}